5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics
    Review

    Rahbar, K.; Bodei, L.; Morris, M. J.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): A multicentre, multicohort, open-label, phase 1b trial
    Journal Article

    Naing, A.; Wong, D. J.; Infante, J. R.; Korn, W. M.; Aljumaily, R.; Papadopoulos, K. P.; Autio, K. A.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • "Was it worth it?'' as a novel, patient-centered metric of the tolerability of cancer therapy
    Meeting Abstract

    Thanarajasingam, G.; Basch, E.; Scher, H. I.; Bennett, A. V.; Mazza, G. L.; Schwab, G.; Weitzman, A. L.; Sloan, J. A.; Rogak, L. J.; Dueck, A. C.
    Quality of Life Research (2019)

    Fulltext@MSK | Save
  • EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors
    Meeting Abstract

    Petrylak, D. P.; Balar, A. V.; O'Donnell, P. H.; McGregor, B. A.; Heath, E. I.; Yu, E. Y.; Galsky, M. D.; Hahn, N. M.; Gartner, E. M.; Pinelli, J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)
    Meeting Abstract

    Zhang, T.; Ballman, K. V.; Choudhury, A. D.; Chen, R. C.; Watt, C.; Wen, Y.; Zemla, T.; Emamekhoo, H.; Gupta, S.; Morris, M. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations
    Meeting Abstract

    Varghese, A. M.; Patel, J. A. A.; Janjigian, Y. Y.; Meng, F.; Selcuklu, S. D.; Zimel, C.; Hyman, D. M.; Iyer, G.; Houck-Loomis, B.; Abou-Alfa, G. K.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)
    Meeting Abstract

    Taplin, M. E.; Gleave, M.; Evans, C. P.; Efstathiou, E.; Kantoff, P. W.; Ross, A.; Shore, N. D.; Briganti, A.; Hadaschik, B. A.; Heidenreich, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350)
    Meeting Abstract

    Subudhi, S. K.; Aparicio, A.; Zurita, A. J.; Doger, B.; Kelly, W. K.; Peer, A.; Rathkopf, D. E.; Karsh, L. I.; Tryon, J. J.; Kothari, N.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors
    Meeting Abstract

    Sonpavde, G.; Manitz, J.; Gao, C.; Hennessy, D.; Makari, D.; Niegisch, G.; Rosenberg, J. E.; Bajorin, D. F.; Grivas, P.; Apolo, A. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas
    Meeting Abstract

    Shoushtari, A. N.; Sanchez-Vega, F.; Kantheti, H.; Callahan, M. K.; Postow, M. A.; Barker, C. A.; Chatila, W. K.; Jonsson, P.; Ariyan, C. E.; Brady, M. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save